Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis
Bibliographic Data
| ID | 15523728 |
|---|---|
| Authors | Gloria Giordano, Lorenzo Tomassini, Ilaria Cuomo (ASL Roma), Emanuela Amici (0009-0003-5347-7160), F Perrini (0000-0003-0789-8071), Gemma Callovini (0000-0001-5987-2362), Alfonso Carannante, Georgios D Kotzalidis (0000-0002-0281-6324, Azienda Ospedaliera Sant'Andrea, corresponding author), Sergio De Filippi (0000-0002-6521-3379), Sergio De Filippis |
| Year | 2020 |
| Volume | 10 |
| Pages | 935-935 |
| Publication date | 2020-01-07 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Psychiatry (JOURNAL) |
| Journal identifiers | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Publisher | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2019.00935 |
| PMID | 31969843 |
| OpenAlex | W2990665555 |
| Language | EN |
| References cited | 81 |
Background: Long-acting injectable (LAI) aripiprazole was found to be efficacious in schizophrenia. In common clinical practice, the use of LAIs is often restricted to chronic patients with frequent relapses and poor adherence. Recently, some investigators advanced the idea of early LAI use also in young people with schizophrenia at their first psychotic episode (FEP). Objective: Our study aimed to assess the effect of LAI aripiprazole once monthly (AOM) in the treatment of FEP in patients aged 18-26 years. Methods: We included 50 patients with DSM-5 schizophrenia as assessed with SCID, and used the Clinical Global Impressions Scale-Severity of Illness (CGI-S) and the Positive and Negative Syndrome Scale (PANSS) to assess symptom severity and the World Health Organization Quality of Life (WHOQOL), the Short Form Health Survey (SF-36) and the Personal and Social Performance Scale (PSP) to assess quality of life (QoL) and global health perception at baseline and 3, 6, 9, and 12 months after the first AOM injection. Results: AOM was associated with a progressive improvement, compared to baseline, of both positive ( p p p p < 0.001). We also observed progressive improvement in QoL and social and personal functioning. Treatment adherence was 78% at study endpoint. Our results support that AOM may improve psychotic symptoms, QoL and social functioning in young FEP patients. Further studies should compare AOM to its oral formulation in the treatment of young patients with schizophrenia at the outset of their illness
Aripiprazole · Global Assessment of Functioning · Positive and Negative Syndrome Scale · Psychiatry · Psychopathology · Psychosis · Quality of life (healthcare · Schizophrenia (object-oriented programming · Bipolar Disorder and Treatment · Clinical Psychology · Medicine · Mental Health and Psychiatry · Psychology · Schizophrenia research and treatment · Internal Medicine
| Highly cited | No |
|---|